- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00630266
Confirmation Trial of the Acorn CorCap Cardiac Support Device (CSD) at the Same Time as Mitral Valve Repair (MVR + CorCap)
Clinical Evaluation of Acorn CorCap Cardiac Support Device Concomitant to MVR - A Confirmatory Trial
The purpose of this study to evaluate patients when they have an Acorn CorCapTM Cardiac Support Device (CSD) placed around their heart for the treatment of heart failure at the same time as their mitral valve surgery.
The CorCapTM CSD is intended to support the heart, potentially preventing further dilation that is associated with progressive heart failure, thereby potentially preserving or improving heart function.
Study Overview
Detailed Description
The Acorn CorCap Cardiac Support Device (CSD) is a new therapy for the treatment of heart failure that is designed to reduce left ventricular dilation, which is one of the most important pathophysiological mechanisms underlying the clinical syndrome of heart failure. The Acorn CorCap CSD is intended to reduce wall stress and support the heart, in order to prevent further dilation that is associated with progressive heart failure. It is designed to result in reduced left ventricular size and improve left ventricluar function, which should result in improved patient functional status.
The purpose of the study is to provide confirmatory data to demonstrate an improved benefit-risk profile in support of a Pre-Market Approval (PMA) application for the Acorn CorCap CSD when placed concomitant to Mitral Valve Repair/Replacement (MVR).
The primary efficacy objective is to evaluate patient functional status after 6 months of follow-up. The safety endpoint is perioperative (30 day) mortality.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Meegan Anderson, RN, BSN, MBA, CCRA
- Phone Number: 651-260-4822
- Email: meegan.anderson@acorncv.com
Study Locations
-
-
Quebec
-
Montreal, Quebec, Canada, H3A 1A1
- Recruiting
- Royal Victoria Hospital, McGill University
-
Contact:
- Charlene Barber, RN
- Phone Number: 36764 514-934-1934
- Email: charlene.barber@muhc.mcgill.ca
-
Principal Investigator:
- Renzo Cecere, MD
-
Principal Investigator:
- Nadia Giannetti, MD
-
-
-
-
California
-
Santa Clara, California, United States, 95051
- Recruiting
- Kaiser Permanente Northern California Heart Transplant Program
-
Contact:
- Patricia Lockyer, RN (CAP)
- Phone Number: 408-851-3826
- Email: patricia.lockyer@kp.org
-
Principal Investigator:
- Dana Weisshaar, MD
-
Principal Investigator:
- Mario Pompili, MD
-
Principal Investigator:
- Vic Melikian, MD
-
Principal Investigator:
- Jay LaBourene, MD
-
Principal Investigator:
- Maria Ansari, MD
-
-
Illinois
-
Oak Lawn, Illinois, United States, 60453
- Recruiting
- Advocate Christ Medical Center
-
Contact:
- Colleen Gallagher, RN, BSN
- Phone Number: 27 708-346-4044
- Email: colleen.gallagher@advocatehealth.com
-
Principal Investigator:
- Pat Pappas, MD
-
Principal Investigator:
- Antone Tatooles, MD
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109-5864
- Recruiting
- University of Michigan
-
Contact:
- Cathie Bloem
- Phone Number: 734-615-6170
- Email: bloem@med.umich.edu
-
Principal Investigator:
- Steven F Bolling, MD
-
Detroit, Michigan, United States, 48202
- Recruiting
- Henry Ford Hospital
-
Contact:
- Karen Leszczynski, RN
- Phone Number: 313-916-3520
- Email: kleszcz1@hfhs.org
-
Principal Investigator:
- Robert Brewer, MD
-
Principal Investigator:
- Hassan W. Nemeh, MD
-
Principal Investigator:
- Barbara Czerska, MD
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68526
- Recruiting
- Nebraska Heart Institute
-
Contact:
- Deb Baehr, LPN
- Phone Number: 402-328-3939
- Email: dbaehr@neheart.com
-
Principal Investigator:
- James Wudel, MD
-
Principal Investigator:
- Deepak Gangahar, MD
-
Principal Investigator:
- Kaliprasad N Ayala, MD
-
Lincoln, Nebraska, United States, 68506
- Recruiting
- BryanLGH Medical Center
-
Contact:
- Shari Harre, RN
- Phone Number: 402-483-3373
- Email: shari@bhi-1.com
-
Principal Investigator:
- Edward Raines, MD
-
Principal Investigator:
- Steven Krueger, MD
-
-
New Jersey
-
Newark, New Jersey, United States, 07112
- Recruiting
- Newark Beth Israel
-
Contact:
- Laura Adams, RN
- Phone Number: 973-926-8451
- Email: ladams@sbhcs.com
-
Principal Investigator:
- Mark J Zucker, MD, JD
-
Principal Investigator:
- Margarita Camacho, MD
-
Principal Investigator:
- Ravi Karanam, MD
-
Principal Investigator:
- David A Baran, MD
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic Foundation
-
Contact:
- Barb Gus, RN
- Phone Number: 216-445-6552
- Email: gusb@ccf.org
-
Principal Investigator:
- Nicholas Smedira, MD
-
-
Pennsylvania
-
Lancaster, Pennsylvania, United States, 17603
- Recruiting
- Lancaster General Hospital
-
Contact:
- Linda Bowman, RN, BS, CCRC
- Phone Number: 203 717-290-6681
- Email: lbowman@lancasterheart.org
-
Principal Investigator:
- Jeff Cope, MD
-
Principal Investigator:
- Roy Small, MD
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Hospital of the University of Pennsylvania
-
Contact:
- Jessica L Howard
- Phone Number: 215-410-6987
- Email: jessica.howard@uphs.upenn.edu
-
Principal Investigator:
- Michael A Acker, MD
-
Principal Investigator:
- Mariell Jessup, MD
-
Principal Investigator:
- Y. Joseph Woo, MD
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Penn-Presbyterian Medical Center
-
Principal Investigator:
- Y. Joseph Woo, MD
-
Contact:
- Marsha R. Watts, RN, BSN
- Phone Number: 215-662-9595
- Email: marsha.watts@uphs.upenn.edu
-
Principal Investigator:
- Michael A. Acker, MD
-
Principal Investigator:
- W. Clark Hargrove, MD
-
Principal Investigator:
- Rohinton Morris, MD
-
Principal Investigator:
- Ross Zimmer, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Dilated cardiomyopathy of either ischemic or non-ischemic origin
Patients must be on stable, optimally uptitrated medical therapy recommended according to current guidelines as standard of care of heart failure therapy in the United States. This minimally includes:
- Angiotensin-converting enzyme inhibitors (ACE) or alternate if ACE not tolerated for greater than or equal to 1 month prior to enrollment (not required for patients with a mitral valve anomaly that is not likely to respond to medication and requires surgical intervention).
- Treatment with a beta-blocker, unless intolerant, for greater than or equal to 3 months prior to enrollment (not required for patients with a mitral valve anomaly that is not likely to respond to medication and requires surgical intervention).
- Diuretic at least "prn" (as occasion requires).
- Cardiac medications unchanged for greater than or equal to 1 month except for diuretic adjustments (not required for patients with a mitral valve anomaly that is not likely to respond to medications and requires surgical intervention).
- Adult (18 to 80 years).
- Indexed left ventricular end diastolic dimension (LVEDDi)between 30 mm/m2 and 40 mm/m2 as determined by transthoracic echocardiography.
- Mitral regurgitation (MR) greater than or equal to 2+ and scheduled for mitral valve repair or replacement. Concomitant tricuspid valve repair or replacement (TVR) and/or atrial fibrillation ablation procedures will be permitted.
- Left ventricular ejection fraction (LVEF) less than or equal to 45 percent via transthoracic echocardiography, cardiac catheterization, radionuclide scan, or magnetic resonance imaging
- New York Heart Association Functional Class (NYHA) II, III or IV
- Geographically available for follow-up
- Signed Informed Consent
Exclusion Criteria:
- Inability to reach maximal effort CPX test as defined by the CPX Core Lab
- Planned cardiac surgical procedure other than MVR
- Hypertrophic obstructive cardiomyopathy.
- Significant cardiomegaly, which is estimated to exceed the largest available size of CorCap CSD.
- Expectation of existing cardiothoracic adhesions that would cause an inability to gain complete circumferential access to the heart.
- Existing patent CABG.
- Candidates for surgical revascularization as determined by an angiogram. Patients with ischemic heart disease who have not had an angiogram within the past 3 years and in whom lesions amenable to revascularization cannot be excluded should have a repeat angiogram.
- Any condition considered a contraindication for extracorporeal circulation.
- Use of Intra aortic Balloon Pump (IABP), intravenous inotropic or vasoactive agents within 30 days prior to enrollment. Pre-operative hemodynamic optimization with IABP, IV inotropes or vasoactive agents may be permitted if it is scheduled to occur within 48 hours of planned index surgery.
- Current or anticipated need for left ventricular assist device (LVAD) or cardiac replacement device.
- Anticipated need for heart transplant within the next two years.
- Acute myocardial infarction (AMI), unstable angina, or cerebral vascular accident (CVA) or Transient Ischemic Attack (TIA) within past 3 months.
- Percutaneous coronary intervention (PCI) or transmyocardial laser revascularization (TMR or PMR) within the past 3 months.
- Presence of arrhythmias causing hemodynamic instability, history of resuscitated sudden death without subsequent treatment with implantable defibrillator or amiodarone, or atrial fibrillation with a ventricular rate greater than 100 bpm on medication.
- Co-morbid condition that reduces life expectancy to less than 1 year.
- Active infection.
- Pregnancy at the time of enrollment. (Women of child bearing potential must have a negative serum pregnancy test within two weeks prior to enrollment, or be using hormonal contraceptives or intrauterine devices.)
- Enrolled in another investigational study that would confound interpretation of trial results.
- Patients who participated as control patients in the previous CorCap PMA randomized trial.
- Unable to comply with protocol-required follow-up (as judged by primary investigator or referring cardiologist).
Late stage heart failure with increased surgical risk as defined by the presence of four or more of the following:
- LVEDD greater than 80 mm/m2
- Resting systolic blood pressure (BP) less than or equal to 80 mm Hg (on clinical exam)
- Atrial fibrillation at time of enrollment or paced rhythm with underlying atrial fibrillation
- Heart failure greater than or equal to 8 years
- 6 minute walk less than or equal to 350 meters (1148 feet)
- POV2 less than or equal to 13 ml/kg/min (CPX test)
- Exercise induced increase in systolic BP less than 10 percent (CPX test)
- Previous cardiac surgery
- BUN greater than 100 mg/dl
- Cachexia (clinical impression)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in patient functional status as evaluated using the Minnesota Living with Heart Failure questionnaire
Time Frame: 6 month follow-up
|
6 month follow-up
|
Change in maximal exercise tolerance evaluated using cardiopulmonary exercise (CPX) testing (peak VO2 exercise test)
Time Frame: 6 Month follow-up
|
6 Month follow-up
|
Change in sub-maximal exercise tolerance as evaluated using the Six Minute Walk test.
Time Frame: 6 months
|
6 months
|
Number of patients who have died (all-cause) or had a re-hospitalization due to heart failure.
Time Frame: 6 months
|
6 months
|
Peri-operative mortality, death occuring within 30 days of baseline surgery.
Time Frame: 30 days
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Rate of death and SAEs overall and for each specific type of event
Time Frame: 6 months
|
6 months
|
Change in patient functional status as evaluated using the Minnesota Living with Heart Failure Questionnaire
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Randall Starling, MD, The Cleveland Clinic
- Principal Investigator: Michael A Acker, MD, Hospital of the University of Pennsylvania, Cardiovascular Medicine; Penn-Presbyterian Medical Center
- Principal Investigator: Mario Pompili, MD, Kaiser Permanente Northern California Heart Transplant Program
- Principal Investigator: James Wudel, MD, Nebraska Heart Institute
- Principal Investigator: Mark J Zucker, MD, JD, Newark Beth Israel
- Principal Investigator: Renzo Cecere, MD, Royal Victoria Hospital, McGill University
- Principal Investigator: Pat Pappas, MD, Advocate Christ Medical Center
- Principal Investigator: Robert Brewer, MD, Henry Ford Hospital
- Principal Investigator: Jeff Cope, MD, Lancaster General Hospital
- Principal Investigator: Edward Raines, MD, BryanLGH Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 47-1389
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
US Department of Veterans AffairsCompleted
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Duke University; St. Paul's Hospital... and other collaboratorsActive, not recruitingHeart Diseases | Heart Failure | Transplant; Failure, Heart | Heart Transplant Failure and Rejection | Heart Failure,Congestive | Transplant FailureCanada, United States
Clinical Trials on CorCap CSD
-
PepsiCo Global R&DTerminatedSweetness Liking AdaptationUnited States
-
PepsiCo Global R&DCompletedSweetness Liking AdaptationUnited States
-
Ace Cells Lab LimitedUnknownPsoriasis | Atopic Dermatitis | Chronic EczemaSerbia, United Kingdom
-
PepsiCo Global R&DCompletedSweetness Liking AdaptationMexico
-
University of California, Los AngelesOregon Health and Science UniversityRecruitingVentricular Fibrillation | Ventricular Tachycardia | Sudden Cardiac Death | CardiomyopathyUnited States
-
Invictus Medical, Inc.WithdrawnOther Preterm InfantsUnited States
-
University Hospital, GhentEAU Young Academic Urologists Urolithiasis and Endourology Working Group; European... and other collaboratorsEnrolling by invitationNephrolithiasis | Urolithiasis | UreterolithiasisBelgium
-
Xipeng WangUnknownCesarean Scar DiverticulaChina
-
Skane University HospitalLund UniversityRecruitingAlzheimer Disease | Mild Cognitive Impairment | Mild DementiaSweden
-
National Institute of Allergy and Infectious Diseases...Boehringer IngelheimCompletedHIV Infections | Peripheral Nervous System DiseaseUnited States, Tanzania